Mycoplasma Testing Market - By Product Type (Instruments, Kits & Reagents, Services), By Technique (PCR, ELISA, Microbial Culturing Techniques, Enzymatic Methods), By Application (Cell Line Testing, Virus Testing), By End-use & Forecast, 2024 - 2032

Mycoplasma Testing Market - By Product Type (Instruments, Kits & Reagents, Services), By Technique (PCR, ELISA, Microbial Culturing Techniques, Enzymatic Methods), By Application (Cell Line Testing, Virus Testing), By End-use & Forecast, 2024 - 2032

Mycoplasma Testing Market size is expected to grow at over 11.9% CAGR during 2024-2032, driven by increasing prevalence of mycoplasma contamination in cell culture-based research and the strong need for biopharmaceuticals and vaccines. The growing demand for biopharmaceuticals and vaccines is a significant driver propelling the market expansion. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, are becoming the cornerstone of modern medicine. As per WHO, in 2021 alone, the global supply of vaccines amounted to 16 billion doses, valued at approximately US$ 141 billion.

As biopharmaceuticals and vaccines are manufactured using complex cell culture processes, ensuring their safety and efficacy has turned paramount. Mycoplasma contamination poses a serious risk to the quality and safety of these products. Contaminated biopharmaceuticals and vaccines can lead to adverse effects on patients, regulatory issues, and financial losses for manufacturers. To meet regulatory requirements and maintain product quality, biopharmaceutical and vaccine manufacturers are increasingly investing in advanced mycoplasma testing solutions. These solutions enable rapid and accurate detection of mycoplasma contamination while helping to safeguard the integrity of biopharmaceutical and vaccine production processes.

The mycoplasma testing market is classified based on product type, application, technique, end-use and region.

The market size from the instruments product type segment is expected to grow substantially at 11.8% CAGR from 2024 to 2032. Advanced instrumentation technologies, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) offer rapid and accurate detection of mycoplasma contamination in cell cultures and biopharmaceutical products. These instruments enable high-throughput screening and automation, enhancing efficiency and productivity in mycoplasma testing laboratories. Additionally, the advent of innovative portable instruments facilitates on-site testing, further reducing turnaround times and enabling real-time monitoring of contamination risks.

By technique, the mycoplasma testing industry from the enzyme-linked immunosorbent assay (ELISA) segment is poised to record 11.8% CAGR through 2032. ELISA-based assays leverage the specificity of antigen-antibody interactions to detect and quantify mycoplasma antigens or antibodies in biological samples. With its high sensitivity and scalability, ELISA also offers a cost-effective solution for routine mycoplasma screening in research laboratories and biopharmaceutical manufacturing facilities.

Asia Pacific mycoplasma testing industry is set to expand at 12.3% CAGR till 2032, driven by rapid industrialization, increasing investments in biopharmaceutical R&D, and the growing awareness about product safety and quality standards. Countries, such as China, India, and Japan are witnessing a surge in biopharmaceutical manufacturing activities, fueled by favorable government initiatives, infrastructure development, and technological advancements. Moreover, the presence of a large pool of skilled labor and cost-effective manufacturing capabilities will further augment the regional market expansion.